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Abstract
Objective: With the progressive aging of the human population, there is an inexorable decline in muscle mass,
strength and function. Anabolic supplementation with testosterone has been shown to effectively restore muscle
mass in both young and elderly men. In this study, we were interested in identifying serum factors that change
with age in two distinct age groups of healthy men, and whether these factors were affected by testosterone
supplementation.
Methods: We measured the protein levels of a number of serum biomarkers using a combination of banked
serum samples from older men (60 to 75 years) and younger men (ages 18 to 35), as well as new serum
specimens obtained through collaboration. We compared baseline levels of all biomarkers between young and
older men. In addition, we evaluated potential changes in these biomarker levels in association with testosterone
dose (low dose defined as 125 mg per week or below compared to high dose defined as 300 mg per week or
above) in our banked specimens.
Results: We identified nine serum biomarkers that differed between the young and older subjects. These age-
associated biomarkers included: insulin-like growth factor (IGF1), N-terminal propeptide of type III collagen (PIIINP),
monokine induced by gamma interferon (MIG), epithelial-derived neutrophil-activating peptide 78 (ENA78),
interleukin 7 (IL-7), p40 subunit of interleukin 12 (IL-12p40), macrophage inflammatory protein 1b (MIP-1b), platelet
derived growth factor b (PDGFb) and interferon-inducible protein 10 (IP-10). We further observed testosterone
dose-associated changes in some but not all age related markers: IGF1, PIIINP, leptin, MIG and ENA78. Gains in lean
mass were confirmed by dual energy X-ray absorptiometry (DEXA).
Conclusions: Results from this study suggest that there are potential phenotypic biomarkers in serum that can be
associated with healthy aging and that some but not all of these biomarkers reflect gains in muscle mass upon
testosterone administration.
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Introduction
As the general population ages, there is an increased
prevalence of loss in muscle mass, raising the risk for
frailty, declines in functional mobility, and early mortal-
i t y[ 1 - 4 ] .L o s so fl e a nm u s c l ec a na l s ob eac o m o r b i d
condition in multiple chronic and acute disorders
including cancer cachexia, HIV-associated weight loss,
inflammatory sepsis, and age-associated sarcopenia
[5-8]. Biomarkers for healthy aging identifiable in the
serum would be of substantial use in detecting age asso-
ciated morbidities and initiating therapeutic pro-ana-
bolic treatment.
Anabolic supplementation is broadly recognized to
increase muscle mass in both elderly and young indivi-
duals [9,10]. Testosterone displays a dose dependent
effect on gains of lean muscle mass and cross-sectional
fiber area in both older and younger men [6,9,11-15].
However, because in some populations testosterone
administration poses undesirable side effects, there is a
motivation for identifying alternative, broadly effective
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tor modulators (SARMs) that improve muscle mass and
physical function [16-18]. Therefore, the utility of serum
biomarkers would help to gauge pro-anabolic activity of
SARMs and therefore be of substantial value in clinical
research to ameliorate declines in muscle mass and
function.
In this study we were interested in identifying age-
associated biomarkers for healthy aging and evaluating
whether biomarkers that differ between healthy young
and older men at baseline, also differ in response to
graded doses of testosterone. To achieve this, we used
banked serum specimens from younger and older men
to measure selected soluble cytokines and growth fac-
tors, based on predicted biomarkers from previous stu-
dies by us and others [2,15,19-25]. Herein, we report
results from this pilot analysis to identify biomarkers
that change either in association with age and/or testos-
terone dosage.
Methods
Sample Population (Boston, MA)
The samples used for this study were obtained from a
previously reported double-blind, randomized study that
consisted of a 4-week control period, 20-week treatment
period and 16-week recovery period [11,13]. Participants
included sixty young men (age range 18 to 35 years)
and sixty-one older men (age range 60 to 75 years). All
subjects provided informed written consent according to
protocol approved by the Charles Drew University and
Research and Education Institute. Exclusion criteria
included 1) presence of prostate disease defined as can-
cer, an American Urological Association symptom score
of greater than 7, a prostate-specific antigen level greater
than 4 ng/ml, 2) hematocrit above 48%, 3) diabetes mel-
litus, 4) heart problems including myocardial infarction
or congestive heart failure all measured using a 12-lead
electrocardiogram monitoring to exclude symptoms pre-
sent during exercise as well, 5) severe sleep apena, 6)
administration of androgenic steroids in the past year,
7) participation in sports events, resistance training or
moderate to heavy endurance exercise training and 8)
baseline testosterone levels below 300 ng/dL. For more
in depth description of enrollment criteria and physical
function, see Bhasin et al, in [11,13]. Stored serum sam-
ples at baseline and after treatment were used from 20
of the younger men and 19 of the older men based on
availability. Mean baseline testosterone levels for
younger men were 586 ng/dL and 358 ng/dL for older
men.
Sample Population (Houston, TX)
Stored baseline serum samples were used from 20 older
men (age range 60 to 85 yrs) recruited through the
Sealy Center of Aging Volunteer Registry at the Univer-
sity of Texas Medical Branch (UTMB) in Galveston, TX
for inclusion in a randomized double-blinded placebo-
controlled testosterone intervention study. All subjects
provided informed written consent according to the
guidelines established by the UTMB institutional review
board and were medically screened. Qualified subjects
had endogenous testosterone concentrations below 500
ng/dL and were otherwise healthy. To assess medical
eligibility, subjects underwent a battery of tests including
a history and physical examination, complete blood
count, metabolic panel including fasting serum glucose
and insulin, an electrocardiogram (ECG), plasma elec-
trolytes, prostate specific antigen (PSA), liver and renal
function and lipid panel. Subjects were included based
upon their ability to provide regular transportation to
the Clinical Research Center (CRC) at UTMB. Subject
exclusion criteria included the following: 1) serum tes-
tosterone > 500 ng/dL, 2) indication of cardiovascular
disease or heart problems assessed via a resting ECG
and a Bruce protocol exercise stress test, 3) previous
history of angina or myocardial infarction, 4) PSA > 4.0
μg/L, 5) history of prostate cancer, 6) history of severe
benign prostatic hypertrophy, 7) LDL > 200 mg/dL, 8)
hematocrit > 51%, 9) hypertension (>140/90 mmHg),
10) BMI > 35, 11) history of hepatitis or 3 × elevation
of Alk phos, ALT, AST, 12) illnesses including diabetes,
cancer, COPD, sleep apnea or any other causing disabil-
ity, 13) bone related disorders, 14) DEXA lumbar score
> -2.5, 15) currently taking Coumadin, glucocorticoids,
androgens, or anti-bone-resorptive agents, and 16) regu-
lar physical exercise. These inclusion/exclusion criteria
reflect those recommended by the Clinical Guidelines
Subcommittee Task Force of The Endocrine Society[26]
and previously published trials with testosterone and
older men [27,28]. Mean baseline testosterone levels for
these older men were 320 ng/dL.
Testosterone supplementation (Boston, MA)
Serum samples were obtained from men who partici-
pated in a randomized testosterone supplementation
trial. Men were treated with monthly injections of a
long-acting GnRH agonist (Lupron depot, 7.5 mg; TAP,
North Chicago, IL) to suppress endogenous testosterone
production, and concomitantly weekly injections of one
of five doses of testosterone enanthate (Delastryl, Savi-
ent Pharmaceuticals, NJ) [11]. Based on dichotomous
functional outcomes in previous reports, testosterone
doses were categorized as low (i.e., 25 mg, 50 mg, and
125 mg) and high (i.e., 300 mg and 600 mg).
Biomarker measurements
The serum specimens were selected based on quality
and availability. Quality was determined by visual
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been collected, centrifuged and stored at similar condi-
tions in both places. Serum factors were measured at
two time intervals: early in the study, i.e., at baseline or
within the first two weeks of starting GnRH and testos-
terone treatment, and later in the study, i.e., twenty
weeks after initiation of GnRH and testosterone treat-
ment. Insulin-like growth factor I (IGF1) was measured
using an enzyme-linked immunosorbent assay (ELISA)
using a non-extraction IGF-1 ELISA kit (Diagnostic Sys-
tems Laboratories, TX) in both young and old at base-
line and after treatment. Pro-collagen III N-terminal
peptide (PIIINP) was measured using validated equili-
brium radioimmunoassay (RIA) (Orion Diagnostics,
Espoo, Finland) as described previously[15,29] in both
the young and the old subjects at baseline and after tes-
tosterone supplementation.
The remaining serum factors were measured using a
multiplex Luminex platform (Panomics, Fremont, CA) as
described previously [30]. This assay uses xMAP technol-
ogy, a multi-analyte profiling Luminex technology, to
detect and quantify multiple protein targets. The samples
were run on a LiquiChip (Qiagen) and were analyzed
using Qiagen Liquichip Analyzer software (Version
1.0.5.17455). A 35-plex was run on serum from the young
men measuring ENA78, Eotaxin, FGF Basic, G-CSF, GM-
CSF, GRO-a,I F N g,I L 1 a,I L 1 b, IL-10, IL-12(p40), IL-12
(p70), IL-13, IL-15, IL-17, IL-17F, IL-1RA, IL-2, IL-4, IL-5,
IL-6, IL-7, IL-8, IP10, Leptin, MCP-3, MIG, MIP1a,
MIP1b,N G F ,P D G F - B B ,R A N T E S ,T N F a and TNFb at
baseline and after testosterone treatment. For those bio-
markers that showed a change with testosterone treatment
in the young, another 3-plex was run on serum from the
older men treated with testosterone at baseline and after
treatment measuring leptin, MIG and ENA78. A 30-plex
assay was run to measure baseline cytokine levels of a
separate group of older men before treatment measuring
eotaxin, FGF basic, GCSF, GM-CSF, GROa,I F N g,I L 1 a,
IL1b, IL-10, IL-12(p40), IL-12(p70), IL-13, IL-17A, IL-2,
IL-4, IL-5, IL-6, IL-7, IL-8. IP-10, MCP-1, MCP-3, MIP-
1a,M I P - 1 b,N G F ,P D G F - B B ,R A N T E S ,T N F a,T N F b,
and VEGF. Values outside of the range of the standard
curve were omitted for the multiplex assays. The lower
limit of detection for these analytes was 1 pg/ml. The CV
range for inter-assay variability for the analytes was 6.73%
- 17.25%, with an average of 12.24%.
Statistical Methods
Baseline values of biomarkers were compared between
younger and older men using a parametric two-sample t-
test assuming unequal variances and a non-parametric
two-sample Wilcoxon rank-sum test giving similar p-
values. The determination of significance in biomarker
response was based on a matched pair analysis of early
versus late levels, and a bivariate categorical analysis of tes-
tosterone dose (low versus high) and age (younger men
versus older men), using a parametric two-sample t-test
with unequal variances and a non-parametric two-sample
Wilcoxon rank-sum test with similar results. Statistical
analyses were carried out in STATA version 8.0 (Stata
Corp, College Station, Tex) and JMP 8.0.2 (SAS Institute
Inc, Cary, NC). Values shown are all displayed as the mean
plus/minus standard deviation unless otherwise indicated.
Box plots are shown as quantiles, with the median (line in
box), quartile range (edges of box), and extremes (vertical
lines and points). In single-plex assays, siginificance was set
at p < 0.05. In multiplex assays, a p-value < 0.05 was used
to denote statististical significance while a p-value < 0.05/
10 = 0.005 was used to take into account multiple compar-
isons using Bonferrorni correction.
Results
Study Population Characteristics
The study population consisted of healthy younger men
(18-35 years old) and healthy older men (60-75 years old).
We screened selected serum chemokines, cytokines,
growth factors and angiogenic factors that we expected to
change with age and possibly testosterone administration
based on previous studies of aging and anabolic supple-
mentation [2,15,19-24]. Serum samples were screened
within the first two weeks of testosterone treatment and at
week 20, the end of treatment period, to look for changes
associated with testosterone dosage. Summary characteris-
tics of the sampled population of younger and older men
used for our serum data are shown in Table 1.
Age related serum profile
T h er e s u l t so fo u rm u l t i p l e xa s s a yi d e n t i f yn i n es e r u m
proteins that differed (significance p < 0.005) between
Table 1 Characteristics of study population
Young Old P
value
Age (yr) 27 ± 5 (53) 68 ± 7 (39) <0.001
Height (cm) 175 ± 7 (53) 175 ± 7 (39) 0.9683
Weight (kg) 74.9 ± 10.0
(53)
84.3 ± 13.1
(39)
0.0003
Body mass index (%) 24 ± 3 (53) 27 ± 4 (39) <0.001
Serum total testosterone
(ng/dl)
586 ± 190
(53)
339 ± 95 (39) <0.001
Population Houston, TX N/A 358 ± 86 (20) N/A
Population Boston, MA 586 ± 190
(53)
320 ± 103
(19)
N/A
Lean Body Mass (mg/cm
2) 57336 ± 7209
(52)
58545 ± 7033
(39)
0.4245
Baseline characteristics of subjects evaluated in this study are shown. The
number of subject used for each baseline value is indicated in parenthesis.
The values are displayed as plus/minus standard deviation. The p-values are
based on a Student t-test.
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nine serum proteins decreased with age: IGF-1, PIIINP,
MIP-1b, IP-10, IL-7, IL-12p40, PDGFb and eotaxin. The
ninth serum protein, MIG showed higher levels in the
older men relative to the younger men. All other ana-
lytes were below detection or not significant. These
pilot data suggest that serum profiling may be a useful
strategy to gauge healthy aging. However, because these
data only use measurements at two age intervals, it
remains unclear whether these biomarkers change
monotonically with age. To address the relationship
between each of the serum biomarkers we measured the
Pearson’s correlation, as shown in Table 2. Six biomar-
kers (MIP-1b, IP-10, IL-7, IL-12p40, PDGFb and
eotaxin) displayed robust r
2 values ≥ 0.75. To evaluate
potential networks between these biomarkers, we uti-
lized Ingenuity Pathway analysis (IPA) and observed
that Akt, NFkB and TGFb signaling were common path-
ways among five of these biomarkers, MIP-1b, IP-10, IL-
7, IL-12p40, PDGFb (data not shown), possibly suggest-
ing that growth, inflammatory and fibrotic regulatory
mechanisms, respectively contribute to the biomarker
profile.
Testosterone related response in serum biomarkers
Testosterone supplementation has been shown to
increase muscle mass in both young and older men. We
were interested in seeing if the factors affected by age
were also responsive to testosterone supplementation
and in finding markers for testosterone supplementation
that are robust in both the young and the old. We eval-
uated the response to graded doses of testosterone in
relation to a young age group (Figure 2), an older age
group (Figure 3) as well as both groups combined (Fig-
ure 4). Due to the small sample size, we based our ana-
lysis on two groups, low dosage (25 mg per week to 125
mg per week) and high dosage (greater than 300 mg per
week) of testosterone, looking at the change in biomar-
ker levels between the baseline and the end of treat-
ment. Based on this approach, we observed three serum
factors measured in single-plex assays showed a signifi-
cant change in association with testosterone dose in the
young, with significance values of p < 0.05 for each
independent assay. These include PIIINP, leptin, and
IGF-1 (Figure 2). We also observed a significant differ-
ence with testosterone dosage in levels of ENA78 and
MIG, however due to a small sample size (n = 2), these
p=<0.0001 p=0.0032 p=<0.0001
(n=50) (n=27) (n=13) (n=36) (n=10) (n=20)
p=0.0048 p=0.0027 p=<0.0001
(n=10) (n=19) (n=10) (n=19) (n=10) (n=18)
p=0.0002
p=0.0007 p=<0.0001
(n =10) (n =11)
(n=10) (n=20) (n=6) (n=18)
(n 10) (n 11)
Figure 1 Baseline levels of biomarkers in young and old men. We evaluated a number of serum cytokines and chemokines in banked
samples of older and younger men at baseline. Nine factors showed a significant change with age at these two groups (p-values from Student
t-test < 0.05), and maintained statistically significant differences even after correcting for multiple comparison (p-value < 0.005).
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DEXA displayed a similar trend change as seen in the
young men at a p-value of ≤0.05 for each independent
assay (Figure 3). Notably, IGF1 and PIIINP showed a
trend change but did not reach significance. This may
be due to the small sample size of the older population
and/or the sampling time of the baseline values (within
first two weeks) in the young, since these biomarkers
m a yh a v ea l r e a d yb e g u nt or i s ea n dt h e r e b ya f f e c tt h e
change observed. When the data from older men and
younger men were combined, we observed that three of
the biomarkers seen in the young, i.e., IGF1, PIIINP and
leptin, as well as DEXA, remained significant using a p-
value of ≤0.05 for each independent assay (Figure 4).
These data indicate that a subset of biomarkers asso-
ciated with healthy aging men also change with testos-
terone administration, given the limits of detection for
the assays used in this study. Whether a similar profile
of anabolic change occurs with exercise or physical
function improvements remains an important question
in efforts to more fully understand the limits of andro-
gen improvements and specificity. These data also
represent the first comparative evaluation of biomarkers
in young and old subjects receiving equivalent testoster-
one supplementation.
Discussion
In this pilot study we describe serum proteins that
change in association with healthy aging among men
between the ages of 18 and 35 compared with older
men between the ages of 60 and 85. We provide evi-
dence that a subset of these biomarkers, but not all,
appear to be responsive to anabolic administration.
T h e s ed a t as u p p o r tt h eh i g hl i k e l i h o o do fas e r u m
p=<0.0001 p=0.0198
(n=30) (n=22) (n=6) (n=7)
p=<0.0001 p=0.0046
(6 ) (4 ) (n=29) (n=21) (n=6) (n=4)
Figure 2 Biomarker response based on testosterone dose in
the young. We evaluated the change in biomarkers that differ
significantly between low and higher doses of testosterone in
younger subjects. P-values are indicated based on a Student t-test.
p=0.0013 p=0.0518
(n=10) (n=10) (n=4) (n=3)
p=0.0439 p=0.1123
(n=10) (n=8) (n=7) (n=9)
Figure 3 Biomarker response based on testosterone dose in
the older group. We evaluated the change in biomarkers that
differ significantly between low and higher doses of testosterone in
older subjects. Leptin was found to be significant to a p-value of <
0.05, however both PIIINP and IGF1 showed a trend change. P-
values are indicated based on a Student t-test.
Table 2 Correlation between Baseline Markers.
Leptin IL5 MCP1 VEGF PIIINP PDGFBB IGF1 Eotaxin IL7 IP10 MIP1b IL12(p40)
Leptin 0.50 -0.28 0.09 0.16 0.10 -0.26 0.02 0.11 -0.06 -0.11 -0.15
IL5 0.50 0.42 0.50 0.04 0.01 -0.23 0.00 0.09 0.02 -0.15 -0.18
MCP1 -0.28 0.42 -0.04 0.10 -0.07 -0.57 -0.30 -0.04 0.65 0.54 -0.06
VEGF 0.09 0.50 -0.04 -0.34 0.51 0.29 0.50 0.35 0.34 0.14 -0.43
PIIINP 0.16 0.04 0.10 -0.34 0.46 0.34 0.44 0.57 0.71 0.43 0.62
PDGFBB 0.10 0.01 -0.07 0.51 0.46 0.62 0.68 0.85 0.79 0.82 0.85
IGF1 -0.26 -0.23 -0.57 0.29 0.34 0.62 0.43 0.54 0.52 0.62 0.69
Eotaxin 0.02 0.00 -0.30 0.50 0.44 0.68 0.43 0.75 0.82 0.64 0.69
IL7 0.11 0.09 -0.04 0.35 0.57 0.85 0.54 0.75 0.69 0.67 0.65
IP10 -0.06 0.02 0.65 0.34 0.71 0.79 0.52 0.82 0.69 0.73 0.80
MIP1b -0.11 -0.15 0.54 0.14 0.43 0.82 0.62 0.64 0.67 0.73 0.89
IL-12(p40) -0.15 -0.18 -0.06 -0.43 0.62 0.85 0.69 0.69 0.65 0.80 0.89
A pairwise Pearson’s correlation was done to evaluate the relationship between biomarker levels in the young and old subjects combined. The r
2 values for each
pairwise correlation is shown. The r
2 values ≥ 0.75 were used to identify networks using Ingenuity Pathway Analysis (IPA). In data not shown Akt, NFB and TGFb
pathways were common among these biomarkers.
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response profiles for therapeutic androgen administra-
tion in older and younger men, particularly when mea-
sured against a reliable age reference group for baseline
biomarker levels. Thus, the use of biomarkers in evalu-
ating anabolic response would benefit from studies that
precisely define the profile of biomarker change during
healthy aging to adequately gauge the effect(s) of gains
associated with anabolic therapy.
Of the serum biomarkers screened at baseline in both
healthy young and older men, we provide evidence for
nine that displayed differences in baseline levels at two
different age groups: IGF1, PDGFBB, PIIINP, eotaxin,
IP-10, IL-12(p40), IL-7, MIP1b and MIG. IGF1 levels,
have been shown previously to decrease with increased
age and have been associated with muscle declines [31].
PIIINP, a marker of remodeling and collagen synthesis
has not been previously studied with aging. The declines
in PIIINP levels in older men suggest a possible
decrease in remodeling with age. The remaining immu-
noregulatory biomarkers collectively suggest a possible
decrease in T-cell and neutrophil response with healthy
aging that could influence muscle maintenance with
aging [32-38]. Pathway analysis using IPA for signaling
networks common to these biomarkers highlight a
potential role for Akt, NF and TGFb pathways, all of
which have been independently associated with aging
[39-42]. The correlated changes in these biomarkers
suggest that perhaps a change in one of these markers
may be predictive of changes in other networked bio-
markers as an aggregate. However, this possibility of
aggregate biomarker profiles will require further study
with larger sampling than was available in this pilot
study.
Previous studies on the effects of testosterone supple-
mentation have indicated that similar gains in muscle
strength and fat free mass are observed in older men com-
pared with younger men [11,13]. Previous separate studies
have addressed individual serum biomarkers that change
in association with anabolic administration (e.g., leptin,
IGF-1) in the young [11,22] and old [23,27]. Importantly,
our study confirms a recent study showing that PIIINP
levels increase with testosterone and predict gains in lean
muscle mass in both young men and older men [15].
Although we do confirm concordant gains with some bio-
markers, we also notice that despite similar gains in mus-
cle strength and mass, older men differed from younger
men in baseline levels of biomarkers and in the response
profile of these markers associated with testosterone sup-
plementation. This suggests, at least for this limited set of
biomarkers, and in these subjects, that gains in muscle
mass and potentially associated gains in physical function
do not display simple concordance with the serum profile.
This may suggest the existence of complex mechanisms
for testosterone response that will require further study.
Additional biomarkers that accurately reflect anabolic
response would assist in more accurately defining anabolic
therapeutic outcomes as well as other approaches for
gains in muscle mass and function, e.g., exercise and other
function promoting therapeutics. The direct and com-
bined comparative study described in this report validates
the robustness and non-equivalency of multiple markers
in association with dose and age - an observation that has
not been fully recognized to date.
Finally, previous studies have shown that testosterone
levels generally decline with age in men [17,43]. Whether
there is a feedback relationship between age dependent
declines in testosterone and biomarkers is beyond the
scope of this study but remains an intriguing possibility.
The dampened biomarker profile observed with an older
age group compared to a younger age group in this study
suggests that testosterone’s effect on anabolic pathways
may change with age while nevertheless achieving the
same gains in mass and strength. Future studies evaluating
age- and anabolic-dependent shifts in biomarker levels will
assist in identifying novel pathways that can be used to
promote gains in muscle mass across a broad age range.
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